The Latest Breaking News from Nasdaq

Casey's General Stores Inc (NASDAQ:CASY) has launched new BBQ Brisket pizza. Like all Casey's pizzas, the BBQ Brisket pizza features made-from-scratch dough. The summer pie is topped with barbeque sauce, mozzarella and cheddar cheese, hand-trimmed brisket pieces, jalapenos, and red onion, and then drizzled with creamy ranch. Available for a limited time,…

Apple, Inc (NASDAQ: AAPL) was trading down about 1.5% in the premarket session Wednesday, but within the first 30 minutes of trading the stock erased its losses. 

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) revealed positive top line results from the exploratory, open label Phase 2 INSPIRE trial. Based on the positive Phase 2 data, the company will request a meeting with the U.S.

In a paper published by the Beijing Institute of Tracking and Telecommunications Technology, a Chinese researcher urged the Chinese military to track and monitor every satellite in the Starlink network, Bloomberg reports. Tesla, Inc (NASDAQ:TSLA) chief Elon Musk’s satellite service provides internet access in over 30 countries. Ren Yuanzhen cited the pervasiveness, ability…

Guardforce AI Co Ltd (NASDAQ:GFAI) expands its Robotics-as-a-Service (RaaS) business lines with new offices in Tokyo, Japan, and San Francisco, California. The T-series robot for reception services, food delivery robots, and disinfection robots for restaurants, shopping malls, and hotels will be among the robotics solutions offered by GFAI in these two sites. "Opening…

Friday marks the last chance for investors to receive the next dividend payout from Prospect Capital (NASDAQ:PSEC).

Friday marks the last chance for investors to receive the next dividend payout from Seanergy Maritime Hldgs (NASDAQ:SHIP).

A whale with a lot of money to spend has taken a noticeably bullish stance on Micron Technology. Looking at options history for Micron Technology (NASDAQ:MU) we detected 11 strange trades.

Krystal Biotech, Inc. (NASDAQ: KRYS) submits biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) in the treatment of patients with dystrophic epidermolysis bullosa (DEB).